The Commission for the Protection of Competition received a notification of a proposed concentration, regarding the acquisition of the share capital of Biosafe Group SA by General Electric Company, through Biacore International AB.
The target of the proposed concentration is Biosafe Group SA, a company duly registered under the laws of Switzerland and a holding company of a medical technology group that specializes in cell processing systems for cell therapy applications. Specifically, the group's activities relate to bioprocessing (process by which manufactured therapeutic products), regenerative medicine (process that allows the replacement or regeneration of human cells, tissues or organs to restore or create the physiological functions) and storage banks stem cells (for storage and preservation of stem cells in cryogenic tanks).
Biacore International AB, is a company duly registered under the laws of Sweden and is a subsidiary company of General Electric Company. Biacore International AB is a global supplier of products related to protein interaction analysis in the academic, pharmaceutical, biotechnology and diagnostic sector.
General Electric Company is a corporation duly registered under the laws of New York and is active in various sectors including construction, technology and services. Among the business units of General Electric Company is the General Electric Healthcare, which provides health technologies and operates inter alia in the fields of medical imaging, software and information technology, monitoring patients and diagnostics, medicine discovery, biopharmaceutical manufacturing technologies and performance improvement solutions.